18.5 C
New York
Monday, September 20, 2021

Can Alpine Immune Sciences Inc. (ALPN) stock turnaround after strong financial results?

Alpine Immune Sciences Inc. (ALPN) stock went negative in both market session. It lost 6.66% yesterday but the company announced financial results for the fourth quarter and year ended December 31, 2020, late Thursday night, which beat the analyst REVENUE estimates.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Let’s see what’s ALPN financial results say.

Key Highlights for Full Year 2020

  • Alpine Immune Sciences Inc. recorded net losses of $27.9 million for the reported year, compared to $41.9 million for 2019.
  • ALPN collaboration revenue for full-year 2020 was $9.3 million compared to $1.7 million for the previous year.
  • ALPN had cash, cash equivalents, and investments totaling $131.4 million as of December 31, 2020, compared to $1.7 million for the prior year.
  • The company spent $27.2 million in Research and development expenses in 2020 compared to 35.8 million for 2019.
  • General and administrative expenses for the year ended December 31, 2020, were $10.9 million compared to $9.5 million for the year ended December 31, 2019.

Key Highlights for fourth-quarter 2020

  • Alpine Immune Sciences Inc. suffered a net loss of $6.34 million for the reported quarter, compared to $6.14 million for Q4 in 2019.
  • ALPN collaboration revenue for q4 2020 was $5.6 million compared to $0.8 million for the q4 in 2019.
  • The company spent $9.05 million in Research and development expenses in Q4,2020 compared to $5.8 million for the same quarter in 2019.
  • General and administrative expenses for Q4 ended December 31, 2020, were $3.04 million compared to $2.1 million for the fourth quarter ended December 31, 2019.

Corporate updates

  • ALPN promoted Remy Durand, Ph.D. to Chief Business Officer. He joined the Alpine in 2018.
  • Pamela Holland, Ph.D. is appointed as a Senior Vice President, Research:
  • ALPN appointed industry veteran Natasha Hernday to the Board of Directors: Ms. Hernday brings more than 20 years of experience in the corporate sector.

Participation AACR Virtual Annual Meeting I

On March 11 Alpine Immune Sciences, Inc confirmed the planned presentation of two posters at the American Association for Cancer Research (AACR) Virtual Annual Meeting I. the meeting is taking place April 10-15, 2021.

Presentation Title: NEON-1: A first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies. Dr. Mark Voskoboynik will be presenting the poster.

  • Session Category: Phase I Clinical Trials in Progress
  • Session Title: Phase I Clinical Trials in Progress
  • Date Poster Available: Saturday, April 10th
  • Session Type: E-Poster Session
  • Poster Number: CT213

Presentation Title: Engineered variant domain fusion proteins provide checkpoint inhibition and tumourantigen-dependent CD28 costimulation resulting in potent anti-tumour immunity

  • Session Category: Immunology
  • Session Title: Immunomodulatory Agents and Interventions
  • Date Poster Available: Saturday, April 10th
  • Session Type: E-Poster Session
  • Poster Number: 1740

Earlier ALPN participated in Oppenheimer 31st Annual Virtual Healthcare Conference held on March 17, 2021, and in H.C. Wainwright Global Life Sciences Conference held on March 9, 2021

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.